This is
Kineret

A valuable asset for the treatment of IL-1
mediated diseases*

Kineret is indicated for the treatment of several diseases associated with IL-1-mediated inflammation.2

Kineret was first approved in 2001 for the treatment of Rheumatoid Arthritis (RA). Since then, its indications and use have expanded to a broad spectrum of inflammatory conditions. Kineret is included in international treatment guidelines for the management of several autoinflammatory diseases.1,2,3

MODE OF ACTION

Kineret is a targeted treatment that blocks both IL-1α and IL-1β 1

Kineret neutralises the biologic activity of interleukin-1α (IL-1α) and interleukin-1β (IL-1β) by competitively inhibiting their binding to interleukin-1 type I receptor (IL-1RI)1

Read more about Kineret

*Indications

Still’s disease 
Familial Mediterranean Fever (FMF)
Rheumatoid Arthritis (RA)
Cryopyrin-Associated Periodic Syndromes (CAPS)
Covid-19 pneumonia

Still’s disease 

Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.1 Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs).1

Familial Mediterranean Fever (FMF)

Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.1

Rheumatoid Arthritis (RA)

Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.

Cryopyrin-Associated Periodic Syndromes (CAPS)

Kineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above: Cryopyrin-Associated Periodic Syndromes (CAPS) Kineret is indicated for the treatment of CAPS, including: Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) Muckle-Wells Syndrome (MWS) Familial Cold Autoinflammatory Syndrome (FCAS)1

Covid-19 pneumonia

Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.1

SAFETY

Well established safety profile

Kineret is widely considered to be a well-tolerated treatment. The safety profile of Kineret has been well established in several placebo-controlled, randomised trials, as well as clinical use following its first marketing authorisation in 2001.1

Read more about Safety

TOTAL WORLDWIDE EXPOSURE TO KINERET4
>160 000
PATIENT YEARS

Frequently asked questions

How is Kineret administered?
  • Kineret is given in a pre-filled syringe containing 100 mg of anakinra per 0.67 ml (150 mg/ml).1
  • Kineret is given as a subcutaneous injection.1
  • Dosage depends on indication. In children, the dose is determined depending on body weight. Please refer to current SmPC.
How should Kineret be stored?
  • Kineret should be stored in a refrigerator between 2°C and 8°C.1
  • Kineret should not be frozen or shaken.1
  • Kineret should be kept in its original carton and away from light.1

References

  • Swedish Orphan Biovitrum AB (publ). Kineret summary of product characteristics [SmPC]. Latest version available from: https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf
  • Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron K, et al. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. Arthritis Rheumatol. 2022 Jul 1;74(7):1102–21.
  • Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644–51.
  • EMA. Kineret: EPAR - Risk-management plan. Available from: https://www.ema.europa.eu/en/documents/rmp-summary/kineret-epar-risk-management-plan_en.pdf
KINERET® (ANAKINRA) Rx, F. ATC kod: L04AC03. Immunosuppressants, interleukin inhibitors. Therapeutic indications: Rheumatoid Arthritis (RA): Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone. COVID-19: Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml. Periodic fever syndromes: Kineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above: Cryopyrin-Associated Periodic Syndromes (CAPS): Kineret is indicated for the treatment of CAPS, including: - Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) - Muckle-Wells Syndrome (MWS) - Familial Cold Autoinflammatory Syndrome (FCAS). Familial Mediterranean Fever (FMF): Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate. Still's Disease: Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD), with active systemic features of moderate to 3 high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). Warnings and precautions: In clinical studies transient elevations of liver enzymes have been seen. During post-marketing use hepatic events, not affecting liver function, have been reported. Hepatic events in patients with Still's disease predominantly occur during the first month of Kineret treatment. Kineret treatment should not be initiated in patients with neutropenia (ANC < 1.5 x 109 /l). Treatment with Kineret should not be started in patients with active infections. With careful monitoring, treatment with Kineret can continue even during a severe infection. Treatment with Kineret for COVID-19 can continue despite (secondary) infection. Nature and contents of container: 100mg/0.67 ml of solution for injection in a graduated pre-filled syringe, 7 syringes/pack. SPC updated February 2024. For more information: Please consult the published SmPC. Latest update: March 2024 Contact: Swedish Orphan Biovitrum AB, 112 76 Stockholm, telefon 08-697 20 00, www.sobi.se.